3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Completed
11
Withdrawn
2
Recruiting
2
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Gynecologic
1
Conditions
Carcinoma, Hepatocellular
23
Carcinoma, Non-Small-Cell Lung
4
Liver Neoplasms
3
Pancreatic Neoplasms
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Cholangiocarcinoma
2
Biliary Tract Neoplasms
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Mesothelioma
1
Liver Cirrhosis
1
Hepato Cellular Carcinoma
1
Endometrial Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma
1
Adenocarcinoma Of Esophagus
1
Interventions
Bevacizumab
76
Fluorouracil
56
Cetuximab
47
Leucovorin
44
Oxaliplatin
43
pembrolizumab
35
Irinotecan
34
Folfox protocol
24
Capecitabine
24
HMPL-013
22
Specimen Handling
18
trifluridine tipiracil drug combination
16
Nivolumab
15
Blood Specimen Collection
15
Panitumumab
14
regorafenib
13
Magnetic Resonance Spectroscopy
13
Trifluridine
12
Standard of Care
12
Gemcitabine
12
Biopsy
12
Cisplatin
11
sintilimab
10
Interviews as Topic
10
IFL protocol
10
Drug Therapy
10
Carboplatin
9
tislelizumab
8
Trastuzumab
8
Cyclophosphamide
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Colorectal Neoplasms
×
tremelimumab
×
Clear all
NCT06680739
2026-06-01
SERPENTINE
Vall d'Hebron Institute of Oncology
Phase 2
Recruiting
60 enrolled
NCT03539822
2026-01-21
CAMILLA
University of Pittsburgh
Phase 1/2
Recruiting
117 enrolled